WINNIPEG, MANITOBA--(Marketwire - October 16, 2008) - Miraculins Inc. (TSX VENTURE: MOM), a medical diagnostic company focused on developing and commercializing diagnostic tests for unmet clinical needs is pleased to announce the enrollment of its first patient in the second pivotal study for the Company's P2V™ prostate cancer diagnostic test. The study will be conducted at the Winnipeg Clinic under the guidance of Principal Investigator, urologist, Dr. Patrick Cho. Samples collected from the study will be tested using recently developed Luminex based assays for both PSP94 and Vitronectin, the two proteins that form the P2V™ test.
